Medical - Devices
Compare Stocks
5 / 10Stock Comparison
IINN vs DBVT vs AVAV vs ALKS vs INVA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Aerospace & Defense
Biotechnology
Biotechnology
IINN vs DBVT vs AVAV vs ALKS vs INVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Aerospace & Defense | Biotechnology | Biotechnology |
| Market Cap | $11M | $1712.35T | $8.40B | $5.90B | $1.93B |
| Revenue (TTM) | $289K | $0.00 | $1.61B | $1.56B | $424M |
| Net Income (TTM) | $-13M | $-168M | $-224M | $153M | $504M |
| Gross Margin | 0.7% | — | 21.8% | 65.4% | 76.2% |
| Operating Margin | 45.1% | — | -8.3% | 12.3% | 14.8% |
| Forward P/E | — | — | 58.4x | 24.8x | 11.9x |
| Total Debt | $3M | $22M | $64M | $70M | $269M |
| Cash & Equiv. | $5M | $194M | $41M | $1.12B | $551M |
IINN vs DBVT vs AVAV vs ALKS vs INVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Inspira Technologie… (IINN) | 100 | 11.5 | -88.5% |
| DBV Technologies S.… (DBVT) | 100 | 38.4 | -61.6% |
| AeroVironment, Inc. (AVAV) | 100 | 166.4 | +66.4% |
| Alkermes plc (ALKS) | 100 | 136.8 | +36.8% |
| Innoviva, Inc. (INVA) | 100 | 160.8 | +60.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IINN vs DBVT vs AVAV vs ALKS vs INVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IINN plays a supporting role in this comparison — it may shine differently against other peers.
DBVT is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs IINN's -16.3%
AVAV lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.
INVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
- 94.9% 10Y total return vs AVAV's 498.3%
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.5% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (11.9x vs 24.8x) | |
| Quality / Margins | 118.9% margin vs IINN's -43.7% | |
| Stability / Safety | Beta 0.13 vs AVAV's 1.57 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs IINN's -16.3% | |
| Efficiency (ROA) | 32.4% ROA vs IINN's -275.8%, ROIC 14.2% vs 0.5% |
IINN vs DBVT vs AVAV vs ALKS vs INVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
IINN vs DBVT vs AVAV vs ALKS vs INVA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INVA leads in 3 of 6 categories
ALKS leads 1 • IINN leads 0 • DBVT leads 0 • AVAV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AVAV and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to IINN's -43.7%. On growth, AVAV holds the edge at +143.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $289,000 | $0 | $1.6B | $1.6B | $424M |
| EBITDAEarnings before interest/tax | $13M | -$112M | $82M | $212M | $86M |
| Net IncomeAfter-tax profit | -$13M | -$168M | -$224M | $153M | $504M |
| Free Cash FlowCash after capex | $0 | -$151M | -$183M | $392M | $181M |
| Gross MarginGross profit ÷ Revenue | +0.7% | — | +21.8% | +65.4% | +76.2% |
| Operating MarginEBIT ÷ Revenue | +45.1% | — | -8.3% | +12.3% | +14.8% |
| Net MarginNet income ÷ Revenue | -43.7% | — | -13.9% | +9.8% | +118.9% |
| FCF MarginFCF ÷ Revenue | — | — | -11.3% | +25.1% | +42.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +143.4% | +28.2% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +36.8% | +91.5% | -51.5% | -4.1% | +4.0% |
Valuation Metrics
INVA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 94% valuation discount to AVAV's 108.5x P/E. On an enterprise value basis, INVA's 8.1x EV/EBITDA is more attractive than IINN's 726.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $11M | $1712.35T | $8.4B | $5.9B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $8M | $1712.35T | $8.4B | $4.9B | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | -750.00x | -0.76x | 108.50x | 24.76x | 6.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 58.41x | — | 11.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.67x |
| EV / EBITDAEnterprise value multiple | 726.48x | — | 102.96x | 17.25x | 8.10x |
| Price / SalesMarket cap ÷ Revenue | — | — | 10.23x | 4.00x | 4.55x |
| Price / BookPrice ÷ Book value/share | 1.93x | 0.66x | 5.34x | 3.28x | 1.65x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 12.28x | 9.88x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-4 for IINN. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IINN's 0.58x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs IINN's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.7% | -130.2% | -6.4% | +8.8% | +46.5% |
| ROA (TTM)Return on assets | -2.8% | -89.0% | -5.0% | +5.4% | +32.4% |
| ROICReturn on invested capital | +0.5% | — | +3.6% | +18.9% | +14.2% |
| ROCEReturn on capital employed | +0.2% | -145.7% | +4.5% | +14.2% | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 3 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.58x | 0.13x | 0.07x | 0.04x | 0.23x |
| Net DebtTotal debt minus cash | -$3M | -$172M | $23M | -$1.0B | -$282M |
| Cash & Equiv.Liquid assets | $5M | $194M | $41M | $1.1B | $551M |
| Total DebtShort + long-term debt | $3M | $22M | $64M | $70M | $269M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x | -5.99x | 32.30x | 63.45x |
Total Returns (Dividends Reinvested)
INVA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $947 for IINN. Over the past 12 months, DBVT leads with a +110.4% total return vs IINN's -16.3%. The 3-year compound annual growth rate (CAGR) favors INVA at 25.0% vs IINN's -31.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -51.1% | +4.9% | -34.4% | +25.3% | +14.7% |
| 1-Year ReturnPast 12 months | -16.3% | +110.4% | +5.1% | +16.5% | +21.7% |
| 3-Year ReturnCumulative with dividends | -68.3% | +19.7% | +63.1% | +14.5% | +95.2% |
| 5-Year ReturnCumulative with dividends | -90.5% | -69.1% | +53.7% | +60.9% | +94.4% |
| 10-Year ReturnCumulative with dividends | -90.5% | -87.0% | +498.3% | -11.0% | +94.9% |
| CAGR (3Y)Annualised 3-year return | -31.8% | +6.2% | +17.7% | +4.6% | +25.0% |
Risk & Volatility
Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than AVAV's 1.57 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs IINN's 27.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.52x | 1.26x | 1.57x | 1.06x | 0.13x |
| 52-Week HighHighest price in past year | $1.65 | $26.18 | $417.86 | $36.60 | $25.15 |
| 52-Week LowLowest price in past year | $0.34 | $7.53 | $155.69 | $25.17 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +27.3% | +76.3% | +40.2% | +96.7% | +90.7% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 48.1 | 39.8 | 60.2 | 39.9 |
| Avg Volume (50D)Average daily shares traded | 292K | 252K | 1.7M | 2.3M | 621K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", AVAV as "Buy", ALKS as "Buy", INVA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $343.60 | $44.00 | $37.67 |
| # AnalystsCovering analysts | — | 15 | 28 | 28 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.5% | +0.2% |
INVA leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ALKS leads in 1 (Profitability & Efficiency). 1 tied.
IINN vs DBVT vs AVAV vs ALKS vs INVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IINN or DBVT or AVAV or ALKS or INVA a better buy right now?
For growth investors, Innoviva, Inc.
(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IINN or DBVT or AVAV or ALKS or INVA?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus AeroVironment, Inc. at 108. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x.
03Which is the better long-term investment — IINN or DBVT or AVAV or ALKS or INVA?
Over the past 5 years, Innoviva, Inc.
(INVA) delivered a total return of +94. 4%, compared to -90. 5% for Inspira Technologies Oxy B. H. N. Ltd. (IINN). Over 10 years, the gap is even starker: AVAV returned +498. 3% versus IINN's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IINN or DBVT or AVAV or ALKS or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus AeroVironment, Inc. 's 1. 57β — meaning AVAV is approximately 1141% more volatile than INVA relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 58% for Inspira Technologies Oxy B. H. N. Ltd. — giving it more financial flexibility in a downturn.
05Which is growing faster — IINN or DBVT or AVAV or ALKS or INVA?
By revenue growth (latest reported year), Innoviva, Inc.
(INVA) is pulling ahead at 18. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, AVAV leads at 22. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IINN or DBVT or AVAV or ALKS or INVA?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -43. 7% for Inspira Technologies Oxy B. H. N. Ltd. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IINN leads at 45. 1% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IINN or DBVT or AVAV or ALKS or INVA more undervalued right now?
On forward earnings alone, Innoviva, Inc.
(INVA) trades at 11. 9x forward P/E versus 58. 4x for AeroVironment, Inc. — 46. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — IINN or DBVT or AVAV or ALKS or INVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is IINN or DBVT or AVAV or ALKS or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Inspira Technologies Oxy B. H. N. Ltd. (IINN) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, IINN: -90. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IINN and DBVT and AVAV and ALKS and INVA?
These companies operate in different sectors (IINN (Healthcare) and DBVT (Healthcare) and AVAV (Industrials) and ALKS (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: IINN is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; AVAV is a small-cap quality compounder stock; ALKS is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.